Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Ultimo, NSW, 2007, Australia; Faculty of Health, Australian Research Centre in Complementary and Integrative Medicine, University of Technology Sydney, Ultimo, NSW, 2007, Australia.
Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Ultimo, NSW, 2007, Australia.
Chem Biol Interact. 2024 May 25;395:111009. doi: 10.1016/j.cbi.2024.111009. Epub 2024 Apr 17.
The escalating prevalence of lung diseases underscores the need for innovative therapies. Dysbiosis in human body microbiome has emerged as a significant factor in these diseases, indicating a potential role for synbiotics in restoring microbial equilibrium. However, effective delivery of synbiotics to the target site remains challenging. Here, we aim to explore suitable nanoparticles for encapsulating synbiotics tailored for applications in lung diseases. Nanoencapsulation has emerged as a prominent strategy to address the delivery challenges of synbiotics in this context. Through a comprehensive review, we assess the potential of nanoparticles in facilitating synbiotic delivery and their structural adaptability for this purpose. Our review reveals that nanoparticles such as nanocellulose, starch, and chitosan exhibit high potential for synbiotic encapsulation. These offer flexibility in structure design and synthesis, making them promising candidates for addressing delivery challenges in lung diseases. Furthermore, our analysis highlights that synbiotics, when compared to probiotics alone, demonstrate superior anti-inflammatory, antioxidant, antibacterial and anticancer activities. This review underscores the promising role of nanoparticle-encapsulated synbiotics as a targeted and effective therapeutic approach for lung diseases, contributing valuable insights into the potential of nanomedicine in revolutionizing treatment strategies for respiratory conditions, ultimately paving the way for future advancements in this field.
肺部疾病的患病率不断上升,凸显出对创新疗法的需求。人体微生物组的生态失调已成为这些疾病的一个重要因素,表明共生元在恢复微生物平衡方面可能具有作用。然而,将共生元有效递送到靶部位仍然具有挑战性。在这里,我们旨在探索适合封装共生元的纳米粒子,以应用于肺部疾病。纳米封装已成为解决共生元在这种情况下递药挑战的突出策略。通过全面的综述,我们评估了纳米粒子在促进共生元递药方面的潜力及其在这方面的结构适应性。我们的综述表明,纳米纤维素、淀粉和壳聚糖等纳米粒子具有很高的共生元封装潜力。这些在结构设计和合成方面具有灵活性,是解决肺部疾病递药挑战的有前途的候选物。此外,我们的分析表明,与单独的益生菌相比,共生元表现出更好的抗炎、抗氧化、抗菌和抗癌活性。本综述强调了纳米粒子封装的共生元作为肺部疾病靶向和有效治疗方法的有前途的作用,为纳米医学在改变呼吸状况的治疗策略方面的潜力提供了有价值的见解,最终为该领域的未来发展铺平了道路。